[Autologous hematopoietic cells for severe autoimmune diseases: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) for immune monitoring and biobanking].
Suivi immunologique et collection biologique en vue de l’analyse de la réponse clinique après autogreffe de moelle pour maladies auto-immunes : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Autogreffe de cellules hématopoïétiques
Autoimmune diseases
Autologous hematopoietic cell transplantation
Biobanking
Collection biologique
Immune reconstitution
Maladies auto-immunes
Post-transplantation immune follow-up
Reconstitution immunologique
Suivi immunologique post-autogreffe
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
04
02
2021
revised:
25
02
2021
accepted:
02
03
2021
pubmed:
18
7
2021
medline:
5
1
2022
entrez:
17
7
2021
Statut:
ppublish
Résumé
Autologous hematopoietic cell transplantation (AHCT) is a new treatment option for patients with severe autoimmune diseases (AD), based on the use of intensive or myeloablative chemotherapy to eradicate the pathogenic autoreactive immune cells and to allow the installation of a new and tolerant immune system during immune reconstitution process. Immune reconstitution analysis after AHCT is required for patients clinical follow-up and to further identify biological and immunological markers of the clinical response to develop individualized AHCT protocols. These MATHEC-SFGM-TC good clinical practice guidelines were developed by a multidisciplinary group of experts including members of the french reference center for stem Cell Therapy in Auto-immune Diseases (MATHEC), hematologists from the French speaking Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and experts in immune monitoring and biobanking. The objectives are to provide practical recommandations for immune monitoring and biobanking of samples in patients with AD undergoing AHCT, for routine care purposes and investigational studies.
Identifiants
pubmed: 34272057
pii: S0007-4551(21)00206-X
doi: 10.1016/j.bulcan.2021.03.020
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
S72-S81Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.